氨茶碱对健康人外周血T细胞及CD4~+亚群凋亡的影响

目的观察氨茶碱对分离培养的健康人外周血T细胞及CD4+亚群凋亡的影响。方法密度梯度离心法及尼龙棉柱法分离健康成年人外周血T细胞,及CD8阴性选择磁性分离健康成年人外周血CD4+T细胞。分两部分进行:①外周血T细胞分对照组、氨茶碱组(0.14～18μg/ml),培养72h后用流式细胞术检测凋亡率变化;②CD4+T细胞分对照组、小剂量氨茶碱组(1.13μg/ml)培养48～72h后用流式细胞术检测凋亡率变化。结果①T细胞的分离纯度为81.3%～94.5%,CD4+T细胞的分离纯度为84%～90%;②(0.14～18μg/ml)氨茶碱共培养人外周血T细胞72h后,其中氨茶碱1.13～18μg/ml组凋亡率差异有统计学意义(P值均<0.05);氨茶碱0.14～0.56μg/ml组凋亡率与阴性对照组比较差异无统计学意义;③氨茶碱1.13μg/ml组干预后,培养CD4+T细胞48～72h,经流式细胞术检测凋亡率,与阴性对照组相比,P值均<0.05,48h的凋亡率与72h者相比,差异有统计学意义(P<0.05)。结论小剂量氨茶碱(1.13μg/ml)可诱导人外周血T细胞和CD4+T细胞凋亡率增加。     

慢性丙型肝炎患者CD4+CD25+调节性T细胞表达增加

目的:探讨CD4+CD25+调节性T(Treg)细胞在慢性丙型肝炎患者免疫下调中的意义.方法:流式细胞仪检测慢性丙型肝炎患者外周血中CD4+CD25+Treg细胞的数量;与CD4+CD25-T细胞共同培养,检测其抑制功能;流式细胞仪检测其对CD4+CD25-T细胞合成IFN-γ和IL-4的影响;RT-PCR检测CD4+CD25+Treg细胞中Foxp3的mRNA表达.结果:CD4+CD25+Treg细胞约占慢性丙型肝炎患者外周血中CD4+T细胞的14.1±1.6%,显著高于正常对照5.3±0.8%(P＜0.01),显著抑制CD4+T细胞的增殖(P=0.002),以及合成IFN-γ.CD4+CD25+Treg 细胞高表达Foxp3.结论:持续性HCV感染患者CD4+CD25+Treg细胞表达增加,特异性抑制Th1细胞反应.     

支气管哮喘大鼠CD4+CD25+T细胞的变化及地塞米松干预作用的研究

目的 研究支气管哮喘(简称哮喘)大鼠模型支气管肺泡灌洗液(BALF)、血液、脾脏CD4+CD25+T细胞的变化,及地塞米松对CD4+CD25+T细胞的影响.方法 50只SD大鼠随机分为5组,空白对照(A)组,哮喘(B)组,地塞米松1(C)组、地塞米松2(D)组,地塞米松3(E)组.A组第l天给予腹腔注射生理盐水l ml,第15～21天每天给予生理盐水雾化.B、C、D、E组用卵蛋白建立哮喘大鼠模型,第1天,每只大鼠腹腔注射抗原l ml(卵蛋白1 mg+灭活百日咳杆菌9×106个+氢氧化铝干粉100 mg)混悬液,第15～21天给予1%的卵蛋白雾化30 min,C、D、E组于雾化后分别给予腹腔注射地塞米松0.2 mg/kg、1 mg/kg、2 mg/kg.采用流式细胞仪检测的方法 ,观察大鼠体内BALF、外周血、脾脏CD4+CD25+T细胞的变化及使用不同剂量地塞米松后对其的影响.结果 B组BALF、外周血、脾脏CD4+CD25+T细胞表达占CD4+T细胞的百分比分别是(42.21±5.62)%、(12.69±2.70)%、(11.15±1.05)%,A组结果 分别是(18.76±5.85)%、(6.21±1.73)%、(7.85±2.13)%.B组与A组比较,差异均具有统计学意义(P＜0.01,P＜0.01,P＜0.05);C组、D组、E组BALF中CD4+CD25+T细胞占CD4+T细胞的百分比表达分别是(10.49±4.03)%、(13.28±5.12)%、(7.51±5.39)%,显著低于A组和B组,(P＜0.05,P＜0.01);外周血中,C组(6.03±1.43)%、D组(4.88±0.95)%与A组(6.21±1.73)%比较,差异无统计学意义,E组(3.49±0.62)%与C组、A组比较,差异有统计学意义(P＜0.05).脾脏中,C组(7.25±1.82)%、D组(8.63±3.18)%与A组(7.85±2.13)%比较,差异无统计学意义,E组(3.38±1.37)%与C组、D组、A组比较,差异有统计学意义(P＜0.05).结论 CD4+CD25+T细胞在哮喘大鼠体内有明显的优势表达,可能是哮喘发病的机制之一.地塞米松可以抑制CD4+CD25+T细胞的表达.BALF内CD4+CD25+T细胞的变化与外周血和脾脏的变化具有一致性,监测外周血或脾脏CD4+CD25+T细胞变化可了解肺部情况.     

CD4+CD25+调节性T细胞减少对哮喘患者的影响

目的 比较哮喘患者急性发作期和缓解期支气管肺泡灌洗(BALF)中CD4+CD25+调节性T细胞(Treg)数量差异.方法 通过纤维支气管镜从缓解期(25例)及急性发作期(35例)从哮喘患者气道获得BALF,并用流式细胞仪分析技术测CD4+CD25+Treg的细胞数目.结果 哮喘急性发作期BALF中CD4+CD25+Treg细胞数与缓解期比较差异显著,呈下降趋势.结论 Treg数量及与哮喘病情发生发展相关.     

CD+4 CD+25调节性T细胞抑制持续性丙型肝炎病毒感染患者CD+4T细胞反应

目的探讨CD+4 CD+25调节性T细胞(CD+4 CD+25Treg细胞)在持续性HCV感染患者CD+4 T细胞下调中的意义.方法流式细胞术检测慢性丙型肝炎患者外周血中CD+4 CD+25Treg细胞的数量以及细胞内因子的合成;与正常人或患者CD+4 CD-25 T细胞共同培养,检测其抑制功能;RT-PCR检测Foxp3的mRNA表达.结果 CD+4 CD+25Treg细胞约占慢性丙型肝炎患者外周血中CD+4 T细胞的(13.5±1.8)%,高于正常对照(5.3±0.8)% (P=0.004);主要合成IL-10,高表达Foxp3;CD+4 CD+25Treg细胞显著抑制CD+4 T细胞的增殖,以及合成IFNγ,并且抑制活性较正常人增高(P=0.034),这种作用不依赖IL-10和转化生长因子β.结论持续性HCV感染患者CD+4 CD+25Treg细胞表达增加,抑制活性增强,特异性抑制Th1反应.     

扩张型心肌病患者CD4~+CD25~+Foxp3~+ T细胞的检测及意义

目的:探讨扩张型心肌病(DCM)患者外周血CD4+CD25+Foxp3+T细胞的水平及意义。方法:采用流式细胞术检测DCM患者30例及健康对照组20例外周血CD4+CD25+T细胞和CD4+CD25+Foxp3+T细胞的比例。结果:DCM患者外周血CD4+CD25+T细胞占CD4+T细胞的比例为(8.53±1.64)%,显著低于健康对照组的(11.4±2.17)%,P0.01;DCM患者CD4+CD25+Foxp3+T细胞占CD4+T细胞比例为(0.99±0.54)%,显著低于健康对照组的(1.55±0.55)%,P0.01;且DCM患者心功能越差,CD4+CD25+Foxp3+T细胞占CD4+T细胞的比例越低。结论:DCM患者调节性T细胞比例的减少,可能打破了自身免疫耐受,发生了针对心肌抗原的自身免疫反应,参与了DCM的发病。     

结核病患者外周血CD4+CD25+ T淋巴细胞凋亡及FOXp3表达情况观察

目的初步观察分离培养的结核病患者外周血CD4+CD25+ T淋巴细胞凋亡及其表面特征性标志物FOXp3的表达情况。方法采用密度梯度离心法及尼龙棉柱法分离结核病患者外周血T淋巴细胞,磁性细胞分离器(MACS)分离得到CD4+CD25+ T淋巴细胞,体外培养72 h后分别利用电镜及流式细胞仪观察、检测各分组(结核病组、健康对照组)细胞的凋亡率及FOXp3的表达。结果 MACS可成功分离CD4+CD25+ T淋巴细胞,纯度可达81.1%～84.7%。结核病组较健康对照组外周血CD4+CD25+ T淋巴细胞计数增多,凋亡率增加,FOXp3表达增高(P均<0.05)。结论 FOXp3高表达的CD4+CD25+ T淋巴细胞在结核病的免疫调节过程中起着重要作用,并且与CD4+CD25+ T淋巴细胞的凋亡密切相关。     

CD4+CD25+FOXP3+调节性T细胞与结直肠癌关系研究进展

天然的CD4+CD25+FOXP3+调节性T细胞(Treg)为目前研究最为深入的一类Treg,是Sakaguchi等[1]1995年首先发现在体内外均具有独特抑制功能的T细胞亚群.研究发现Treg在乳腺癌、卵巢癌、肺癌以及肝癌等患者外周血和肿瘤局部微环境中比例增高,且数目与患者肿瘤进展程度和预后、生存率呈负相关[2-6].本文现对CD4+CD25+FOXP3+Treg与结直肠癌(CRC)的相关研究综述如下.     

胰岛素抵抗的慢性丙型肝炎患者外周血CD4+CD25+调节性T细胞的数量及其功能

目的 了解胰岛素抵抗的慢性丙型肝炎患者外周血CD4 +CD25+调节性T细胞(Treg)数量和功能的变化.方法 筛选40例HLA-A2+慢性丙型肝炎患者(其中20例合并胰岛素抵抗),流式细胞仪检测患者CD4+CD25+Treg细胞占外周血中CD4+T细胞的频率,液闪计数仪检测对HCV特异性CD8+T细胞增殖的抑制作用,ELISA法检测IFN-y水平.统计学处理采用t检验.结果 胰岛素抵抗的慢性丙型肝炎患者外周血CD4 +CD25+ Treg细胞占CD4+T细胞的(9.5±1.9)％,明显低于慢性丙型肝炎患者的(11.2±2.2)％(t=2.615,P＜0.05).胰岛素抵抗指数(HOMA-IR)≥4患者的CD4+CD25+ Treg细胞比例为(9.0±1.8)％,明显低于HOMA-IR＜4患者的(10.8±2.3)％(t=2.413,P＜0.05).胰岛素抵抗的慢性丙型肝炎患者CD4+CD25+ Treg细胞和去除Treg的外周血单个核细胞(PBMC)共培养上清液中IFN-y为(4 050±580) pg/mL,明显高于慢性丙型肝炎患者的(2 005±330)pg/mL(t=13.705,P＜0.01).HOMA-IR≥4患者IFN-y为(5 682±986)pg/mL,明显高于HOMA-IR＜4患者的(2 819±660) pg/mL(t=7.630,P＜0.01).结论 随着胰岛素抵抗程度加重,慢性丙型肝炎患者外周血CD4+ CD25+ Treg细胞频率减低,对HCV特异性CD8+T细胞增殖的抑制作用减弱.     

耐药肺结核患者支气管肺泡灌洗液CD_4~+ CD_(25)~+ Treg细胞检测

目的研究耐药肺结核患者支气管灌洗液CD+4CD+25Treg细胞水平与非耐药肺结核患者之间的差异。方法采用流式细胞技术测定40例耐药肺结核患者、60例非耐药肺结核患者及50例健康体检者外周血及支气管肺泡灌洗液CD+4CD+25Treg细胞水平,观察三组之间的差别。结果耐药组外周血CD+4CD+25Treg细胞水平(15.50±1.49)%,非耐药组(11.62±2.34)%,对照组(6.74±2.13)%,三组间有统计学差异(P0.05);耐药组支气管肺泡灌洗液CD+4CD+25Treg细胞水平(19.33±2.15)%,非耐药组(15.56±1.98)%,两组间有统计学差异(P0.05)。结论调节性T细胞在耐药肺结核局部病灶中发挥重要的免疫抑制作用,它与肺结核耐药机制的形成可能有关。     

Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes

CD8+CD25+ cells, which expressed high levels of Foxp3, glucocorticoid-induced tumor necrosis factor receptor (GITR), CCR8, tumor necrosis factor receptor 2 (TNFR2), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) mRNAs, were identified in the fibrous septa and medullary areas of human thymus. Activated CD8+CD25+ thymocytes did not produce cytokines, but most of them expressed surface CTLA-4 and transforming growth factor beta1 (TGF-beta1). Like CD4+CD25+, CD8+CD25+ thymocytes suppressed the proliferation of autologous CD25-T cells via a contact-dependent mechanism. The suppressive activity of CD8+CD25+ thymocytes was abrogated by a mixture of anti-CTLA-4 and anti-TGF-beta1 antibodies and it was mediated by their ability to inhibit the expression of the interleukin 2 receptor alpha chain on target T cells. These results demonstrate the existence of a subset of human CD8+CD25+ thymocytes sharing phenotype, functional features, and mechanism of action with CD4+CD25+ T regulatory cells.     

非小细胞肺癌患者CD3+、CD4+、CD8+、CD44+表达的临床研究

目的研究非小细胞肺癌患者外周血淋巴细胞中CD3+、CD4+、CD8+、CD4+4的表达水平。方法取65例非小细胞肺癌患者及22例健康正常人外周静脉血,应用流式细胞仪检验非小细胞肺癌患者(实验组)与健康人外周血淋巴细胞中(对照组)CD3+、CD4+、CD8+、CD4+4的表达水平。结果实验组与对照组CD3+、CD3+CD4+、CD3+CD8+、CD4+4在淋巴细胞中的比例存在显著性差异(P<0.05),其中,实验组占总淋巴细胞的比例分别为48.07±10.33%、30.93±6.68%、17.13±3.37%、55.45±4.35%;对照组CD3+、CD3+CD4+、CD3+CD8+、CD4+4占总淋巴细胞的比例分别为58.83±10.88%、34.89±6.45%、23.91±4.42%、62.85±7.56%;但鳞癌与腺癌组CD4+4的表达无显著性差异(P>0.05),其中,鳞癌组CD4+4所占比例为61.32±8.06%,腺癌组为64.43±6.76%。结论非小细胞肺癌患者外周血T细胞亚群及CD4+4的表达水平较正常组均低,其表达水平与组织类型无关。     

Decrease in CD4+CD25+ and CD8+CD28+ T cells in interstitial pneumonitis associated with rheumatic disease

The expression of CD25 or CD28 on T cells was examined in patients with rheumatic diseases associated with interstitial pneumonitis (IP), in order to investigate the conditions of CD4⁺CD25⁺ regulatory T cells and CD8⁺CD28⁻ suppressor T cells. Fifty-five patients with various rheumatic diseases and 23 normal controls were enrolled. CD4⁺CD25⁺ T cells of patients with IP were significantly decreased in comparison with non-IP patients, and the ratio of CD8⁺CD28⁻ T cells in patients with IP was significantly higher than that in non-IP patients or normal controls. These results for CD8⁺CD28⁻ T cells were in accord with the decrease in CD8⁺CD28⁺ T cells, and may be related to activation-induced CD8⁺CD28⁺ T-cell death. Thus, the abnormality of CD4⁺CD25⁺ regulatory T cells may be related to the pathogenesis of IP, and the survival and activation of CD8⁺ T cells.     

Decrease in CD4+CD25+ and CD8+CD28+ T cells in interstitial pneumonitis associated with rheumatic disease

Abstract

The expression of CD25 or CD28 on T cells was examined in patients with rheumatic diseases associated with interstitial pneumonitis (IP), in order to investigate the conditions of CD4⁺CD25⁺ regulatory T cells and CD8⁺CD28^? suppressor T cells. Fifty-five patients with various rheumatic diseases and 23 normal controls were enrolled. CD4⁺CD25⁺ T cells of patients with IP were significantly decreased in comparison with non-IP patients, and the ratio of CD8⁺CD28^? T cells in patients with IP was significantly higher than that in non-IP patients or normal controls. These results for CD8⁺CD28^? T cells were in accord with the decrease in CD8⁺CD28⁺ T cells, and may be related to activation-induced CD8⁺CD28⁺ T-cell death. Thus, the abnormality of CD4⁺CD25⁺ regulatory T cells may be related to the pathogenesis of IP, and the survival and activation of CD8⁺ T cells.     

CD19+CD5+ cells as indicators of preeclampsia

Preeclampsia is a devastating pregnancy-associated disorder affecting 5% to 8% of pregnant women worldwide. It emerges as an autoimmune-driven disease, and, among others, the autoantibodies against angiotensin type 1 receptor II have been proposed to account for preeclampsia symptoms. Despite much attention focused on describing autoantibodies associated with preeclampsia, there is no clue concerning the cell population producing them. CD19(+)CD5(+) B-1a B cells constitute the main source of natural and polyreactive antibodies, which can be directed against own structures. Here, we aimed to identify the B-cell subpopulation responsible for autoantibody production during preeclampsia and to study their regulation, as well as their possible use as markers for the disease. The frequency of CD19(+)CD5(+) cells in peripheral blood of preeclamptic patients is dramatically increased compared with normal pregnant women as analyzed by flow cytometry. This seems to be driven by the high human chorionic gonadotropin levels present in the serum and placenta supernatant of preeclamptic patients versus normal pregnant women. Not only ≈95% of CD19(+)CD5(+) cells express the human chorionic gonadotropin receptor, but these cells also expand on human chorionic gonadotropin stimulation in a lymphocyte culture. Most importantly, isolated CD19(+)CD5(+) cells produce autoantibodies against angiotensin type 1 receptor II, and CD19(+)CD5(+) cells were further detected in the placenta of preeclamptic but not of normal pregnancies where barely B cells are present. Our results identify a B-cell population able to produce pregnancy-pathological autoantibodies as possible markers for preeclampsia, which opens vast diagnostic and therapeutic applications.     

CD4+CD25+调节性T细胞与支气管哮喘

支气管哮喘是一种常见的慢性呼吸道疾病,其免疫发病机制尚不十分清楚。CD4 CD25 调节性T细胞是一种特殊的调节性T细胞,参与自身免疫调节,维持自身免疫耐受。本文就CD4 CD25 调节性T细胞的特性及与支气管哮喘的发病机制、治疗、预后的研究进展做一综述。     

CD4+ and CD56+ acute monoblastic leukemia.

We report here a patient with acute monoblastic leukemia whose leukemia cells had CD4 (T4) and CD56 (NKH-1) antigens, in addition to CD36 (OKM5) antigen. The leukemia cells did not have NK or ADCC activities. They showed no rearrangements of immunoglobulin heavy (IgH) chain and T cell receptor (TCR)-beta chain genes, indicating that the leukemia cells were nonlymphoid. The presence of this case suggests that leukemia cells could be originated from monocytes with NK-associated antigen without IgH or TCR rearrangements.     

CD4＋CD25＋Treg细胞与支气管哮喘

CD4＋CD25＋Treg细胞的主要作用表现为免疫无能性和免疫抑制性,是外周免疫耐受形成机制的主要组成部分。其主要作用机制为分泌抑制性细胞因子（IL-10和TGF-β）、表达细胞表面分子（CTLA-4、GITR等）及Foxp3等。支气管哮喘患者外周血CD4＋CD25＋Treg功能及数量存在异常,这可能是支气管哮喘发病机制之一。糖皮质激素可以通过影响CD4＋CD25＋Treg的状态起到抑制支气管哮喘气道炎症的作用。     

CD4+ CD56+ Hematodermic Neoplasm Without Cutaneous Involvement

First evidence of cases of haemophilia dates from ancient Egypt, but it was when Queen Victoria from England in the 19th century transmitted this illness to her descendants, when it became known as the “royal disease”. Last decades of the 20th century account for major discoveries that improved the life expectancy and quality of life of these patients. The history and evolution of haemophilia healthcare counts ups and downs. The introduction of prophylactic schemes during the 1970s have proved to be more effective that the classic on-demand replacement of clotting factors, nevertheless many patients managed with frequent plasma transfusions or derived products became infected with the Human Immunodeficiency Virus (HIV) and Hepatitis C virus during the 1980s and 1990s. Recombinant factor VIII inception has decreased the risk of blood borne infections and restored back longer life expectancies. Main concerns for haemophilia healthcare are shifting from the pure clinical aspects to the economic considerations of long-term replacement therapy. Nowadays researchers’ attention has been placed on the future costs and cost-effectiveness of costly long-term treatment. Equity considerations are relevant as well, and alternative options for less affluent countries are under the scope of further research. The aim of this review was to assess the evidence of different treatment options for haemophilia type A over the past four decades, focusing on the most important technological advances that have influenced the natural course of this “royal disease”.